PLA2R1 and acute lymphoblastic leukemia: In the present study, patients were subdivided into groups with standard, medium, and high risk according to the AIEOP-BFM ALL 2009 guidelines and the PLA2R1 promoter methylation on day 15 of the ALL induction treatment was evaluated as biomarker for risk stratification (Fig. 4).